Abstract

Evidence is increasing on the crucial role of the extracellular matrix (ECM) in breast cancer progression, invasion and metastasis with almost all mortality cases owing to metastasis. The epithelial-mesenchymal transition is the first signal of metastasis involving different transcription factors such as Snail, TWIST, and ZEB1. ECM remodeling is a major event promoting cancer invasion and metastasis; where matrix metalloproteinases (MMPs) such as MMP-2, -9, -11, and -14 play vital roles degrading the matrix proteins for cancer spread. The β-D mannuronic acid (MMP inhibitor) has anti-metastatic properties through inhibition of MMP-2, and -9 and could be a potential therapeutic agent. Besides the MMPs, the enzymes such as LOXL2, LOXL4, procollagen lysyl hydroxylase-2, and heparanase also regulate breast cancer progression. The important ECM proteins like integrins (b1-, b5-, and b6- integrins), ECM1 protein, and Hic-5 protein are also actively involved in breast cancer development. The stromal cells such as tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), and adipocytes also contribute in tumor development through different processes. The TAMs become proangiogenic through secretion of VEGF-A and building vessel network for nourishment and invasion of the tumor mass. The latest developments of ECM involvement in breast cancer progression has been discussed in this review and this study will help researchers in designing future work on breast cancer pathogenesis and developing therapy targeted to the ECM components.

Highlights

  • Breast cancer (BC) accounts for 25% of all cancer cases in women, and 12% of overall cancer cases worldwide[1]

  • Comprehensive studies are currently going on related to the involvement of extracellular matrix (ECM) in BC progression, and this review focuses on the latest developments in this regard with possible molecular targets for therapies

  • The ECM constitutes a complex of structural proteins and its reorganization is essential during cancer progression

Read more

Summary

Introduction

Breast cancer (BC) accounts for 25% of all cancer cases in women, and 12% of overall cancer cases worldwide[1]. The extracellular matrix (ECM) plays a crucial role in breast cancer (BC) progression, invasion, and metastasis; elucidating the role of ECM will help in designing therapies targeting different ECM components. Matrix metalloproteinases (MMPs) degrade ECM proteins promoting invasion and metastasis. The LOXL2 protein catalyzes cross-linking of ECM components collagen and elastin and is involved in cancer progression and metastasis.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call